Parts A & C: patients must have either measurable or evaluable disease
Parts B, D & E: patients must have measurable disease for Parts B-B, D-D, E and E; melanoma patients in Part B must have either measurable or evaluable disease; neuroblastoma patients in Parts B and D must be evaluable for MIBG response without evidence of RECIST measurable lesions
Measurable or evaluable disease
Patients must have either measurable or evaluable disease
Patients must have either measurable or evaluable disease
Disease status:\r\n* Part A: Patients must have either measurable or evaluable disease\r\n* Parts B and C: Patients must have measurable disease on imaging
Part A: Patients must have either measurable or evaluable disease
Patients must have either measurable or evaluable disease
Radiologically measurable or clinically evaluable disease
Patients must have either measurable or evaluable disease
Patient must have measurable or evaluable disease
Radiologically measurable and clinically evaluable disease
Metastatic breast cancer (measurable or evaluable including bone metastases only)
Measurable or evaluable disease.
Evaluable disease
Patients must have measurable or evaluable disease
Participants enrolling to the phase I portion of the trial must have evaluable or measurable disease
Measurable or evaluable disease
Evaluable disease; either measurable on imaging or with informative tumor marker.
Participants must have evaluable or measurable disease
Participants enrolling to the phase I portion of the trial must have evaluable or measurable disease
Patients must have measurable or evaluable disease
Part A: Patients must have either measurable or evaluable disease
Patients must have either measurable or evaluable disease
Patients must have measurable or evaluable disease
Measurable or evaluable disease.
Patients must have measurable or evaluable disease
Patients must have measurable or evaluable disease
Patients must have evaluable or measurable disease
Evaluable disease by RANO.
Patients must have either measurable or evaluable disease
Patients must have evaluable OR measurable disease
Presence of radiographically evaluable disease
Measurable disease as defined by irRECIST. Patients with castrate-resistant prostate cancer can have measurable or evaluable disease. Patients with evaluable disease must have documented evidence of progressive disease as defined by any of the following:
Patients must have evaluable disease on imaging
Have evaluable disease
Measurable and/or evaluable disease per Lugano classification
Have evaluable disease
Evidence of evaluable disease
Evidence of measurable or evaluable disease
Participants must have evaluable or measurable disease in accordance with the International Working Group Guidelines for Lymphoma.
Evaluable disease
PHASE I: Patients must have evaluable disease
Measurable or evaluable disease
Evaluable or measurable disease that meets the following criteria:
Patients must have either measurable or evaluable disease
Patients must have either measurable or evaluable disease.
Patient must have either measurable or evaluable tumor
Arms , , : patients should have clinically measurable or evaluable malignant disease
Patients must have measurable or evaluable disease
Radiologically measurable or clinically evaluable disease
Patients must have measurable or evaluable disease
Patient must have evaluable disease
Evidence of measurable or evaluable disease by clinical, radiographic, or laboratory assessment
Patient must have evaluable disease; measurable disease is not required
Patients with DSCRT are not required to have measurable or evaluable disease
Measurable or evaluable disease: measurable disease in  dimensions on imaging studies performed within  weeks of starting treatment
Has evaluable or measurable disease for response assessment
Presence of measurable or evaluable disease.
Patients without measurable or evaluable disease.
For Part , evaluable or measurable disease
PRE-REGISTRATION: Documentation of measurable or evaluable non-measurable disease.
Presence of evaluable disease according to the  Lugano classification.
Patients with evaluable disease will be eligible
Patients must have measurable or evaluable disease
Patients must have either measurable or evaluable disease
Patients must have either measurable or evaluable disease
Patients must have evaluable disease
Patients must have either measurable or evaluable disease
Patients may have measurable or evaluable disease
Disease status:\r\n* Phase  (Part A): Patients must have either measurable and/or evaluable disease\r\n* Phase  (Part B): Patients with neuroblastoma must have proven ALK+ disease with either measurable and/or evaluable disease as indicated below:\r\n** Measurable tumor on magnetic resonance imaging (MRI), computed tomography (CT) scan or X-ray obtained within  weeks prior to study enrollment\r\n** Evaluable tumor by meta-iodobenzyl guanidine I  (MIBG) scan and/or bone marrow involvement with tumor cells seen on routine morphology \r\n* Phase  (Part C): Patients must have proven ALK+ disease with either measurable or evaluable disease
Patients must have measurable or evaluable disease
Evaluable disease;
All patients must have at least ONE site of evaluable disease.
Measurable disease or evaluable disease with relevant tumor marker elevation.
Measurable or evaluable disease
Must have evaluable or measurable disease
Evaluable disease
Measurable or evaluable disease.
Patients must have evaluable disease on MRI imaging
Patients are required to have evaluable disease
Patients must have either measurable or evaluable disease
Presence of measurable or evaluable disease
PHASE I: Either measurable or evaluable disease is allowed
Patients must have measurable or evaluable disease
Patients with measurable or evaluable disease are eligible
Evaluable or measurable disease
Patients must have evaluable disease for response
Patients with recurrence who undergo resection and are left without measurable or evaluable disease are eligible
Patients must have measurable or evaluable disease
Measurable or evaluable disease
Patients must have measurable or evaluable disease
Evaluable/measurable disease Non-CLL B-cell malignancies (Arms A, C, and D):
Radiographically measurable or evaluable disease
Measurable or evaluable disease
The participant has a radiographically measurable tumor. Evaluable disease is acceptable for Part  only
Histologically confirmed, measurable or evaluable disease; patients should have at least one measurable lesion
Radiographically measurable or evaluable disease
Radiographically measurable or evaluable disease
Radiographically measurable or evaluable disease.
Measurable or evaluable disease based on IWCLL criteria
Patients must have evaluable or measurable malignant disease at enrollment
Evaluable disease
Metastatic cancer with evaluable disease
Presence of measurable or evaluable disease
Measurable disease with elevated PSA or evaluable disease (PSA elevation will constitute evaluable disease)
Evaluable disease or disease measurable
Patients must have either measurable or evaluable disease
Have measurable or evaluable disease.
Patients may have measurable or non-measurable but evaluable disease.
Disease status must be that of measurable and/or evaluable disease
Measurable or evaluable disease (as defined in the study protocol)
Measurable or evaluable disease by gadolinium MRI or contrast CT scan; note: patients who have had a gross total resection (GTR) are eligible on the basis of evaluable disease
Measurable or evaluable disease
Measurable or evaluable disease
Patients must have evaluable or measurable tumor(s)
Evaluable or measurable disease
PHASE I: Patients may have measurable or evaluable disease only
Evaluable or measurable disease
At least one measurable lesion or evaluable disease
Patients must have evaluable disease
Patients must have measurable or evaluable disease
Evidence of measurable or evaluable disease
For Parts A and B, participants must have evaluable or measurable disease
Presence of evaluable disease
Must have measurable or evaluable disease
Participants must have measurable or evaluable disease
All patients must have measurable or evaluable disease
Measurable or evaluable disease
